@charitykface's peptide cycling claims need context

What did @charitykface actually say?

The creator described stopping a cluster of compounds, including what sounds like NAD (likely NAD+ precursor supplementation), a GLP-1 receptor agonist (the garbled "Cloe slash Gloe" and "Glooze-ion" almost certainly refers to semaglutide or a similar agent), and "Epitalin" or "Epitide," which is almost certainly Epitalon, a synthetic tetrapeptide. They stated they are "never giving up" Epitalon and are not cycling off it, while continuing something that sounds like "De-Sip," possibly DSIP (Delta Sleep-Inducing Peptide).

To be direct: the audio is genuinely difficult to parse. Several product names are mangled beyond clean identification. That matters, because health claims made in garbled language still reach 15,000+ viewers who may act on them. We will fact-check what can be reasonably identified.

Does the science back this up?

For Epitalon specifically, the evidence base is real but thin and mostly preclinical. The claim that it requires no cycling has no strong human trial support. For NAD precursors and GLP-1 agents, cycling rationale exists but is clinically individualized, not universal.

Epitalon (Ala-Glu-Asp-Gly) is a synthetic pineal peptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation. Animal studies, including Khavinson et al. (2003, Neuroendocrinology Letters), showed telomere elongation effects in cell cultures and extended lifespan in rodents. A small number of human observational studies from the same research group suggested improvements in melatonin rhythm and antioxidant markers in elderly patients. What is missing is large, randomized, double-blind human trials. The "never cycling off" stance is not grounded in any published safety or pharmacokinetic data for humans. That is not a minor caveat. That is the entire evidentiary gap.

What did they get wrong (or right)?

The creator gets credit for one thing: cycling peptides and other compounds is a legitimate practice, not pseudoscience. Receptor desensitization, tachyphylaxis, and HPA axis suppression are real concerns with long-term use of several peptide categories. Stopping NAD supplementation periodically is not harmful and some researchers argue it may help maintain baseline synthesis pathways (Yoshino et al., 2021, Science).

What they get wrong is the "never giving that up" framing around Epitalon. Presenting indefinite, uncycled use of a compound with no long-term human safety data as a personal best practice, to a public audience, is irresponsible. The Khavinson group's own protocols used defined, limited treatment courses, typically 10-day courses repeated seasonally, not continuous uninterrupted use. The creator's framing directly contradicts the source protocols they are presumably drawing from.

The DSIP reference, if that is what "De-Sip" means, is also worth flagging. DSIP research in humans is sparse, with mixed results in sleep studies (Schneider-Helmert, 1984, European Neurology), and its mechanisms remain poorly characterized. "Help it helps" is not a clinical outcome measure.

What should you actually know?

Three things matter here for anyone watching this video and considering similar compound stacks.

First, Epitalon is not FDA-approved and is not commercially available as a regulated pharmaceutical in the United States. Any Epitalon being used is either compounded, sourced from research chemical suppliers, or imported. Compounded peptides are not equivalent to any approved drug, and quality control varies significantly between suppliers. Purity, sterility, and actual peptide content are not guaranteed without third-party testing.

Second, "cycling" is not one-size-fits-all. For GLP-1 receptor agonists, stopping abruptly without medical supervision carries real clinical considerations, including weight rebound documented in the STEP 1 extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism). NAD precursor cycling has a different risk profile entirely. Treating these as interchangeable decisions is medically inaccurate.

Third, no peptide currently in the bioregulatory research space has sufficient human evidence to support a "never stopping" use protocol. If someone is advising you otherwise, ask them to cite the safety data. There likely is none.

Bottom line

This video is a casual personal update, not a protocol recommendation, but the audience does not always register that distinction. The creator's enthusiasm for Epitalon is not inherently wrong, the research is genuinely interesting. But "never giving that up" framed as health wisdom, without flagging the absence of long-term human data, is where this content crosses from anecdote into misinformation by omission.